ArticleFrontiers in oncology2023
Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999-2019.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07343453 (A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
Who cites it
19 citing papers in PubMed.
- ASO Author Reflections: Transection or Reconstruction? Surgical Decision-Making for Brachiocephalic Vein Involvement in Locally Advanced Thymic Epithelial Tumors.Annals of surgical oncology · 2026Article
- The Surgical Outcomes of Brachiocephalic Vein Transection Versus Reconstruction for Locally Advanced Thymic Epithelial Tumors.Annals of surgical oncology · 2026Article
- First-Line Platinum-Based Chemotherapy with Novel Systemic Agents for Unresectable or Metastatic Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis.JTO clinical and research reports · 2026Review
- Thymoma in the United States (2000-2023): Population-Based Incidence, Treatment Patterns, and Survival.Cureus · 2026Article
- Nationwide trends in mediastinal tumor and myasthenia gravis surgery in Japan: a decade claims-based analysis (2014-2023).International journal of clinical oncology · 2026Article
- Long-Term Outcomes of Surgery for Thymic Epithelial Tumors With Pleural Metastases.JTO clinical and research reports · 2026Article
- Impact of Combined Additional Resections on the Surgical Outcomes of Robot-Assisted Resection of Thymic Epithelial Tumors.Journal of surgical oncology · 2026Article
- Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy.Frontiers in oncology · 2026Review
- Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study.Frontiers in oncology · 2026Article
- Hemodynamic response after preoperative embolization in thymoma-associated myasthenia gravis: associations with necrosis, HIF-1α expression, and CD163-positive macrophages.Frontiers in immunology · 2026Article
- Classification of mediastinal compartments: is separation of the superior mediastinum crucial?-a clinical practice review.Mediastinum (Hong Kong, China) · 2026Review
- Oncologic strategies and options for the management of metastatic thymic carcinoma.Mediastinum (Hong Kong, China) · 2026Review
- Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.Cancers · 2025Review
- Robot-Assisted Versus Open Surgery for the Resection of Large Thymomas: A Retrospective Cohort Study.Journal of surgical oncology · 2025Article
- Immunotherapy in thymic epithelial tumors: an attractive dilemma.Investigational new drugs · 2025Review
- Immune aberrations in thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2025Review
- Case Report: Type A invasive thymoma with renal metastasis.Frontiers in oncology · 2025Article
- Development and validation of a scoring model for predicting surgical benefit in patients with Masaoka stage III/IV thymic carcinomas.Gland surgery · 2024Article
- Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mediastinal tumors, particularly non-neuroendocrine thymic epithelial tumors (TET) are relatively uncommon, posing challenges for extensive epidemiological studies. This study presents a comprehensive analysis of these tumors in the United States (US) and Germany (GER) from 1999 to 2019. Methods: Patients aged 0-19 (n=478) and ≥20 years (n=17,459) diagnosed with malignant tumors of the anterior mediastinum were identified from the Surveillance, Epidemiology, and End Results registry (SEER) and the Zentrum für Krebsregisterdaten (ZfKD) databases. Results: Among patients aged ≥20 years, TETs accounted for the most prevalent anterior mediastinal tumors (US/GER: 63%/64%), followed by lymphomas (14%/8%). For patients <20 years, predominant tumors included germ cell tumors (42%/14%), lymphomas (38%/53%), and TETs (10%/27%). The overall annual incidence of thymoma was 2.2/2.64 (US/GER) per million inhabitants and for thymic carcinomas 0.48/0.42. The male-to-female ratio was 1:1.09/1.03, and the mean age 59.48 ± 14.89/61.33 ± 13.94. Individuals with thymomas, but not thymic carcinomas, exhibited a 21%/29% significantly heightened risk of developing secondary malignancies compared to controls with non-thymic primary tumors. Discussion: This study provides a comparative analysis of anterior mediastinal tumors, particularly TETs, in the US and GER over the past two decades. Furthermore, it highlights a significantly elevated incidence of secondary malignancies in thymoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.